Therefore, mixed AChE/BChE inhibitors, such as MF and KP extracts, which exhibit balanced activity against both enzymes, could offer broader therapeutic potential for the AD treatment across both early and late stages. The gene discussed is BCHE; the disease is Alzheimer disease.